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Aim: To co-relate the use of hormonal contraceptives 
with positive Auditory and Vestibular alterations. Methods: 
medical history taking, audiometric test and vestibular test 
was applied to 60 women between the ages of 14 and 35 
years old, and 30 of these women are on oral hormonal 
contraceptive consisting of Estrogen and Progesterone (risk 
group), for 6 months or more, that had no Auditory or 
Vestibular complaints prior to the usage of hormones; and 
30 women that had never used these hormones (control 
group), with no Auditory or Vestibular complaints. Medical 
history was used to select the sample. Results: Based on 
otoneurological findings, through quantitative research, we 
could see the prevailing Irritatative Peripheral Vestibular 
Syndrome and tinnitus in the risk group, without audiometric 
alterations. Conclusion: The use of oral contraceptives can 
provoke functional alterations in the inner ear, specially 
tinnitus and Irritative Peripheral Vestibular Syndrome in 
the risk group; but auditory threshold alterations were not 
evident.
Keywords: hearing, contraceptive, hormone, dizziness, 
tinnitus.
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INTRODUCTION
Women go through monthly reproductive cycles, 
which start during puberty and, usually, last during all their 
reproductive life, stopping at menopause. These cycles 
prepare the female reproductive tract for pregnancy¹.
A gonadotrophin release hormone (GnRH), synthe-
sized by the hypothalamus, stimulates the release of two 
other hormones produced in the pituitary: follicle stimulat-
ing hormone (FSH), and the Luteinizing hormone (LH). 
The former stimulates the development of ovarian follicles 
and the production of estrogen by the follicular cells,  the 
latter triggers ovulation (acts on the release of the second-
ary oocyte) stimulating the follicle cells and the corpus 
luteus to produce progesterone. Estrogen acts specially 
on the reproductive organs functioning and development 
regulation; and progesterone acts stimulating endometrial 
glands to secrete and prepare the endometrium for the 
blastocyst implantation¹.
When the oocyte is not fertilized, the corpus luteus 
starts to degenerate about 10 to 12 days after ovulation; 
estrogen and progesterone levels drop and the secretory 
endometrium enters its ischemic phase, and menstruation 
sets in¹.
Combined estrogen and progesterone pills (con-
traceptive pills), taken orally for a period of three weeks 
have anovulatory action, preventing fertilization from tak-
ing place. This occurs through gonadotrophin secretion 
inhibition by the pituitary acting on the hypothalamus. 
The progesterone agent present in the pill suppresses LH 
secretion and the estrogen agent is responsible for the FSH 
secretion suppression, showing a synergic effect. Besides, 
the estrogen component enhances the action of the pro-
gesterone agents, thus allowing a reduction on the doses 
of progesterone in the pill composition and, consequently, 
reducing its adverse effects2.
The use of these contraceptive pills by women 
may cause different adverse reactions, such as: immune, 
metabolic, nutritional, psychiatric, vascular, ocular, gastro-
intestinal, hepatobiliary, skin, renal/urinary and auditory 
alterations; Central Nervous System disorders, and repro-
ductive system disorders. Moreover, the body may trigger 
vertigo in the pre-menstrual syndrome or during the use 
of these hormones, due to estrogen and progesterone 
concentrations3-10.
Therefore, when vertigo and/or dizziness/hearing 
loss appear, it is necessary to investigate prior use of 
medication; it is necessary to know whether or not the 
symptoms started with the use of some substance or in 
changing a medication dosing¹¹.
Partial or total loss of auditory or vestibular function, 
during or after exposure to medications, solvents and other 
substances is called ototoxicity. Many are the potentially 
ototoxic substances, including cardiovascular drugs, central 
nervous system drugs, muscle relaxants, non-hormonal 
anti-inflammatory, antibiotics, hormones, respiratory tract 
drugs, antihistamines, contraceptive drugs, cytostatic drugs, 
anesthetics, appetite moderators, amongst others12,13.
Body balance depends on the integrity of the ves-
tibular system, the somatosensorial system and vision. 
The labyrinth is responsible for the sense of balance and 
the body’s position in space. Dizziness and vertigo set it 
when something interferes in the normal functioning of 
these systems.
The biochemical integrity of the inner ear liquids 
is important for its proper functioning. The hormonal 
alterations caused by oral hormonal contraceptives may 
impair the homeostasis of labyrinth fluids, because they 
have direct influence over the enzymatic processes and 
on the action of neurtransmitters14.
There are some studies that correlate inner ear 
alterations with the action of hormones, which will be 
reported below. 
The use of oral contraceptives may lower hearing 
thresholds, without altering stapedial reflex14.
There are cases of sudden hearing loss because of 
the use of estrogen and progesterone, alone or in asso-
ciation. The prolonged use of these hormones may cause 
sensorineural hearing loss in the high frequencies, besides 
total or partial vestibular involvement. This is explained 
when we observe labyrinth irrigation, because the vascular 
obstruction of the internal auditory artery brings disorders 
to the territory it irrigates, involving the cochlea, vestibule 
or both14.
Some studies believe that otologic alterations (oto-
sclerosis, hearing loss, progressive hearing loss) in women 
who use oral hormonal contraceptives may not be related 
to this therapy alone15.
In a study carried out with women who used oral 
hormonal contraceptive pills, they observed that in relation 
to hearing capacity and self-perception, this use does not 
cause significant hearing alterations; however, it favors 
tinnitus symptoms. Notwithstanding, in another study, 
women who used oral contraceptives had significant and 
consistent hearing loss in some frequencies, when com-
pared to normal menstrual cycle women who did not use 
the pill16,17.
This correlation between hearing alterations and 
the use of oral hormone contraceptives was observed in 
a case in which a young woman presented with sudden 
sensorineural hearing loss, preceded by tinnitus, and 
recovered after treatment. In this case, tinnitus should 
be considered a warning about the need to interrupt the 
hormonal therapy18.
There are research papers showing that oral con-
traceptives today have less estrogen and progesterone, 
being called “low dose pills”. The reduction on the doses 
of these hormones has significantly reduced sudden hear-
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ing loss in those patients14.
In order to prove the influence of hormones in 
the body, normal pregnant women were submitted to 
vestibular assessment, showing greater sensitivity to mild 
vestibular stimuli, when compared to the control group 
(males), thus proving a labyrinth dysfunction during nor-
mal pregnancy, specially on the first quarter, probably 
secondary to the hormonal action19,20.
In a study with albino guinea pigs, they studied the 
effective estrogen action on the hearing, manifested by an 
increase in brain stem auditory potential thresholds in 47% 
of the animals, thus confirming the ototoxicity potential 
of this hormone21.
Among causes of vertigo, migraine is predominantly 
found among teenagers and adults. The use of oral con-
traceptives, intra-uterine devices or even hysterectomy, 
should be always considered in cases of recurrent chronic 
headaches, for there are indications that the use of a con-
traceptive method, specially hormonal, influence the occur-
rence of this disease. Among persons with migraine, 81% 
were female and 77% are between 16 and 50 years22.
In this study we shall approach the otoneurological 
alterations (hearing loss, tinnitus, vestibular symptoms) ac-
cruing from the use of hormonal contraceptives by women 
for a minimum time period of 6 menstrual cycles. Our goal 
was to correlate the use of oral hormonal contraceptive 
use with possible hearing and vestibular alterations.
METHODS
The present study was carried out from the data 
about patient history, tonal/vocal audiometry and vestibu-
lar exam from 30 women who used the oral hormonal 
contraceptive method and in 30 women who did not use 
it (control group).
In order to select the sample individuals, some cri-
teria were used: females, aged between 14 and 35 years, 
minimum of 6 months on oral hormonal contraceptive with 
estrogen and progesterone, without hearing alterations 
complaints before starting to use hormonal contraceptive, 
and without using any other type of medication. 
To make up the control group, we selected women 
aged between 14 and 35 years, who did not use contra-
ceptive hormones nor any other medication, with neither 
hearing nor vestibular complaints. 
Tonal threshold audiometry of all the patients were 
carried out in a sound proof booth, with the aid of an Am-
plaid A171 audiometer, calibrated according to the ANSI-
69 standard, in 03/19/2003. We assessed the frequencies 
from 250Hz to 8000Hz (air) and 500Hz to 4000Hz (bone), 
according to the method used to determine the descend-
ing-ascending hearing threshold2,3.
The results obtained from the audiometric tests were 
interpreted as to hearing level, according to the criteria 
used by Silman & Silverman, and as to the type of hearing 
loss (mild, moderate, severe, profound)2,4.
Vestibular exams were carried out through the Con-
tronic version 5 device. The tests used were: calibration, 
spontaneous nystagmus (eyes opened and eyes shut), 
semi-spontaneous nystagmus, positional nystagmus (head 
torsion to the right, head torsion to the left, pending head), 
pendular tracking, and post-caloric nystagmus (water at 
44º and 30°) (attachment 3).
After data collection, results were statistically 
treated. We build contingency tables (2 x 2) to describe 
the hearing and vestibular alterations frequence distribu-
tion between the two groups under comparison (risk and 
control groups). In order to check the significance of this 
association between the use of oral hormonal contracep-
tives with hearing and vestibular alterations we used the 
chi-squared test (c2) at a significance level of a = 0.005. 
Both the null and alternative hypothesis considered in 
these tests were, respectively, H0: there is no correlation 
between the use of oral hormonal contraceptives and hear-
ing and vestibular alterations; and Ha: there is a relation 
between the use of oral hormonal contraceptive and hear-
ing/vestibular alterations. Since we had a p value below 
the previously established level of significance a= 0.005), 
the null hypothesis was rejected (H0), thus showing a 
significant association between the use of oral hormonal 
contraceptives and hearing/vestibular alterations.
Ethics: The present study was assessed and ap-
proved by the Ethics and Research committee of the 
Speech Therapy Specialization Clinic (CEFAC) under pro-
tocol # 133/04 and it was approved without risk and with 
the need for a Free and Clarified Informed Consent. 
RESULTS
In the control group, 100% of the sample (30 wom-
en) did not complain of hearing loss, tinnitus or dizziness. 
70% (21 women) complained of sporadic headaches and 
16.7% (5 women), complained of insomnia. In the risk 
group, 100% of the sample (30 women) did not complain 
of hearing loss; 33.3% (10 women) complained of tin-
nitus; 73.3% (22 women) complained of dizziness; 76.7% 
(23 women) reported sporadic headaches and 23.3% (7 
women), insomnia. (Tables 1-4).
In the audiometric test, 100% of the sample (60 
women) had audiometric tests within the normal range, 
compared to 0% of altered audiometric test.
In vestibular testing, the control group showed 
23.3% of the sample (7 women) with irritative peripheral 
vestibular syndrome (IPVS) and 76.7% (23 women) had 
normal vestibular tests (NVT). In the risk group, 83.3% 
(25 women) had irritative peripheral vestibular syndrome 
(IPVS) and 16.7% (5 women) had normal vestibular tests 
(NVT). (Table 5). 
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audiometric tests, corroborating data from some previous 
research. Current contraceptive pills are mainly made up 
of low doses of estrogen and progesterone, thus reducing 
the occurrence of side effects, specially those related to 
the auditory function. Notwithstanding, the occurrence of 
tinnitus in the risk group was significant (c2 = 12.00 and 
p value = 0.000)14-16,18.
Results also point that headache and insomnia 
complaints may not be related to the use of contraceptive 
medication, because there was no difference between the 
number of women in the risk group and in the control 
group who had these symptoms (c2 = 0.341 and p value 
= 0.559).
Notwithstanding, the headaches reported were iden-
tified as sporadic and not as chronic-recurrent (migraine). 
In some scientific findings, migraines are closely related 
to the use of hormones22.
The use of oral hormonal contraceptive pills may 
have significantly influenced the complaint of dizziness 
(c2) = 34.737 and p value = 0.000), since this complaint 
was not seen in the control group3-11,14.
The results of the vestibular tests show the relation-
Table 1. Analysis of tinnitus occurrence in women who used oral 
hormonal contraception for six months or more (risk group), and in 
women who had never used it (control group).
  Tinnitus
Group  Present Absent Total
Risk n 10 20 30
% 33,3 66,7 100,0
Control n 0 30 30
% 0 100,0 100,0
Total n 10 50 60
% 16,7 83,3 100,0
x2 = 12.00 and p value = 0.001
Table 2. Analysis of insomnia occurrence in women who used the oral 
hormonal contraception method for six months or more (risk group), 
an in women who had never used it (control group).
  Insomnia
Group  Present Absent Total
Risk n 7 23 30
% 23,3 76,7 100,0
Control n 5 25 30
% 16,7 83,3 100,0
Total n 12 48 60
% 20,0 80,0 100,0
x2 = 0.417 and p value = 0.519
Table 3. Analysis of the occurrence of sporadic headaches in women 
who used the oral hormonal contraception method for six months 
or more (risk group), an in women who had never used it (control 
group).
  Sporadic headaches
Group  Present Absent Total
Risk n 23 7 30
% 76,7 23,3 100,0
Control n 21 9 30
% 70,0 30,0 100,0
Total n 44 16 60
% 73,3 26,7 100,0
x2 = 0.341 and p value = 0.559
Table 4. Analysis of dizziness occurrence in women who used the oral 
hormonal contraception method for six months or more (risk group), 
an in women who had never used it (control group).
  DIZINESS
Group  Present Absent Total
Risk n 22 8 30
% 73,3 26,7 100,0
Control n 0 30 30
% 0 100,0 100,0
Total n 22 38 60
% 36,7 63,3 100,0
x2=34.737 and p value = 0.000
Table 5. Vestibular test analysis in women who used the oral hormonal 
contraception method for six months or more (risk group), an in women 
who had never used it (control group).
  Vestibular test
Group  IPVS NVT Total
Risk n 25 5 30
% 83,3 16,7 100,0
Control n 7 23 30
% 23,3 76,7 100,0
Total n 32 28 60
% 53,3 46,7 100,0
x2=21.696 and p value = 0.000
IPVS – irritative peripheral vestibular syndrome; NVT – normal vesti-
bular test.
DISCUSSION
Based on the results of this research paper, we can 
see that hearing loss does not seem to be related to the use 
of oral hormonal contraceptives, since both the risk group 
and the control group did not show alterations in their 
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ship between irritative peripheral vestibular syndrome 
and the use of oral hormonal contraceptives, since 25 in 
30 women of the risk group presented IPVS, while only 
7 in 30 women of the control group had such alteration 
(c2 = 21.696 and p value = 0.000). This may be related 
to the influence of these hormones in the homeostasis of 
labyrinth fluids14.
CONCLUSION
We then concluded that the use of oral hormonal 
contraceptives for a period of 6 months or more may cause 
functional alterations to the inner ear, specially tinnitus and 
dizziness, the latter is justified by the significant prevalence 
of irritative peripheral vestibular syndrome in the risk 
group, but did not show hearing threshold alterations. 
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